1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Epigenetics
  3. PARP
  4. PARP2 Isoform

PARP2

 

PARP2 Related Products (41):

Cat. No. Product Name Effect Purity
  • HY-10162
    Olaparib
    Inhibitor 99.98%
    Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively.
  • HY-15147
    XAV-939
    Inhibitor 98.60%
    XAV-939 is a Tankyrase inhibitor.
  • HY-16106
    Talazoparib
    Inhibitor 99.89%
    Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.
  • HY-10619
    Niraparib
    Inhibitor 99.96%
    Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively.
  • HY-10617A
    Rucaparib
    Inhibitor 99.84%
    Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1.
  • HY-121719
    TIQ-A
    Inhibitor 99.65%
    TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC50 of 24 nM for TNKS2.
  • HY-147886
    PARP1-IN-11
    Inhibitor
    PARP1-IN-11 (compound 49) is a potent PARP1 inhibitor with IC50 value of 0.082 µM.
  • HY-10619E
    Niraparib tosylate hydrate
    Inhibitor
    Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively.
  • HY-10129
    Veliparib
    Inhibitor 99.78%
    Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively.
  • HY-13688A
    PJ34
    Inhibitor 98.01%
    PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.
  • HY-10619B
    Niraparib tosylate
    Inhibitor 99.97%
    Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively.
  • HY-13688
    PJ34 hydrochloride
    Inhibitor 99.10%
    PJ34 hydrochloride is an inhibitor of PARP1/2 with IC50 of 110 nM and 86 nM, respectively.
  • HY-102003
    Rucaparib monocamsylate
    Inhibitor 99.82%
    Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1.
  • HY-10619A
    Niraparib hydrochloride
    Inhibitor 99.76%
    Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively.
  • HY-13536
    AZD-2461
    Inhibitor 99.88%
    AZD-2461 is a potent PARP inhibitor, with IC50s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.
  • HY-13990
    NVP-TNKS656
    Inhibitor 99.31%
    NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
  • HY-10617
    Rucaparib phosphate
    Inhibitor 99.76%
    Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1.
  • HY-18954
    NMS-P118
    Inhibitor 99.78%
    NMS-P118 is a potent, orally available, and highly selective PARP-1 Inhibitor for cancer therapy.
  • HY-10130
    Veliparib dihydrochloride
    Inhibitor 99.96%
    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively.
  • HY-137457
    Venadaparib
    Inhibitor 98.03%
    Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively.